Technology

Phathom Pharmaceuticals

$39.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.42 (-1.06%) Today
$0.00 (0.00%) As of 9:36 AM UTC after-hours

Why Robinhood?

You can buy or sell PHAT and other stocks, options, and ETFs commission-free!

About PHAT

Phathom Pharmaceuticals, Inc. Common Stock, also called Phathom Pharmaceuticals, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ. The listed name for PHAT is Phathom Pharmaceuticals, Inc. Common Stock.

CEO
Terrie Curran
Employees
25
Headquarters
Florham Park, New Jersey
Founded
2018
Market Cap
1.23B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
120.57K
High Today
$40.60
Low Today
$38.50
Open Price
$39.55
Volume
122.87K
52 Week High
$64.54
52 Week Low
$22.06

Collections

PHAT Earnings

-$3.97
-$2.65
-$1.32
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 18, Pre-Market

You May Also Like

CUBA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure